Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five

Executive Summary

The finalized generic drug user fee agreement would clear most of the ANDA application backlog by the end of the first program cycle.
Advertisement

Related Content

ANDA Complete Response Letters To Become Routine In 2012
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues
GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience
ANDA User Fee Performance Metrics Revealed
FDA's Medical Countermeasure Program Among Senate Funding Priorities
ANDA User Fee Performance Metrics Revealed
E-Submission Part Of FDA Reg Reform Plan; Alzheimer’s Data Standard About To Debut
FDA, Industry Reach Agreement On Major Portions Of Generic User Fee Program
Generic User Fee Talks: Performance Metrics For Early Years Still Unresolved
Pre-NDA Work Takes Added Importance As PDUFA V Stretches Review Cycle

Topics

Advertisement
UsernamePublicRestriction

Register

PS053751

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel